Skip to main content
Premium Trial:

Request an Annual Quote

T2 Biosystems, Bayer Ink Hemostasis R&D Deal

NEW YORK (GenomeWeb) – T2 Biosystems announced today that it has signed a multi-year deal giving Bayer access to its T2 Magnetic Resonance (T2MR) technology platform for use in its R&D efforts in blood coagulation disorders.

Under the terms of the deal, the companies will use the technology to develop tools and evaluate assays for drug discovery and biomarker research in certain Bayer hemostasis-related programs.

Additional terms were not disclosed.

The T2MR technology uses superparamagnetic nanoparticles to measure the reaction of water molecules in the presence of magnetic fields, which is known as a T2 signal. When a binding event occurs inside a sample, the T2 signal changes, making it possible to detect the presence of an analyte.

The technology is the basis for T2's T2Candida sepsis test and its upcoming T2Bacteria bacterial sepsis assay, which is planned for a 2017 launch.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.